Onkolytische Viren als innovativer Ansatz in der Therapie gastrointestinaler Tumoren

Zusammenfassung

Für die gastroenterologische Onkologie werden zusätzliche Therapiestrategien benötigt, die auf neuartigen Mechanismen basieren und keine Kreuzresistenz hinsichtlich gegenwärtiger Standardtherapien zeigen. Einen dieser Ansätze stellt die Virotherapie dar, bei der replikationskompetente virale Vektoren mit stark ausgeprägter onkolytischer Funktion zum Einsatz kommen und gegenwärtig innerhalb präklinischer und klinischer Studien evaluiert werden. Unter Einsatz der Methodik der molekularen Virologie ist eine Fortentwicklung der momentan verfügbaren Vektorsysteme insbesondere zur Verbesserung der onkolytischen Aktivität, der Tumorselektivität, der Durchwanderungsfähigkeit von Tumoren sowie der Sicherheitsaspekte erforderlich.

Abstract

Gastroenterological oncology requires new strategies with new mechanisms of action and without cross-resistance to currently available treatment regimes. Virotherapy which is based on the employment of replication-competent viral vectors exhibiting strong oncolytic properties is such an approach currently under preclinical/clinical investigation. Techniques of molecular virology are required for further improvement of current vectors, particularly with respect to oncolytic activity, tumour selectivity, tumour spread capacity, and safety.

Virotherapie - Onkolyse - Tumorgentherapie - vermehrungsfähige virale Vektoren

Virotherapy - oncolysis - cancer gene therapy - replication-competent viral vectors

Literatur

• 1 Lal S, Lauer U M, Wessels J T. et al . Suicide Genes: Past, Present, and Future Perspectives.  Immunol Today. 2000;  21 48-54
• 2 Yoon S K, Armentano D, Wands J R. et al . Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice.  Cancer Gene Ther. 2001;  8 573-579
• 3 Bilbao R, Bustos M, Alzuguren P. et al . A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.  Gene Ther. 2000;  7 1824-1832
• 4 Erbs P, Regulier E, Kintz J. et al . In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.  Cancer Res. 2000;  60 3813-3822
• 5 van Dillin I J, Mulder N H, Vaalburg W. et al . Influence of the bystander effect on HSV-tk/GCV gene therapy. A review.  Curr Gene Ther. 2002;  2 307-322
• 6 Elliot G, O’Hare P. Intercellular trafficking and protein delivery by a Herpesvirus structural protein.  Cell. 1997;  88 223-233
• 7 Wybranietz W A, Groß C D, Phelan A. et al . Enhanced suicide gene effect by adenoviral transduction of a VP22-Cytosine deaminase (CD) fusion gene.  Gene Ther. 2001;  8 1654-1664
• 8 Oess S, Hildt E. Identification of a novel cell permeable peptide derived from the Hepatitis B virus surface antigen.  Gene Ther. 2000;  7 750-758
• 9 Kirn D. Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?.  Gene Ther. 2001;  8 89-98
• 10 Ring C JA. Cytolytic viruses as potential anti-cancer agents.  J Gen Virol. 2002;  83 491-502
• 11 Baum C. Replikative Viren in der Krebstherapie.  Forum DKG. 2002;  Sonderheft 1/02 58
• 12 Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review.  Intervirol. 1993;  36 193-214
• 13 Southam C M. Present status of oncolytic virus studies.  NY Acad Sci. 1960;  22 656-673
• 14 Bluming A Z, Ziegler J L. Regressin of Burkitt's lymphoma in association with measles infection.  Lancet. 1971;  ii 105-106
• 15 Taqi A M, Abdurrahman M B, Yakubu A M. et al . Regression of Hodgkin's disease after measles.  Lancet. 1981;  i 1112
• 16 Kirn D H. Replicating oncolytic viruses: an overview.  Expert Opin Investig Drugs. 1996;  5 753-762
• 17 Tollefson A, Scaria A, Hermiston T W. et al . The adenovirus death protein (E3 - 11.6K) is required at late stages of infection for efficient lysis and release of adenovirus from infected cells.  J Virol. 1996;  70 2296-2306
• 18 Everett H, McFadden G. Apoptosis: an innate immune response to virus infection.  Trends in Microbiol. 1999;  7 160-165
• 19 Basu S, Binder R J, Suto R. et al . Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.  Int Immunol. 2000;  12 1539-1546
• 20 Berwin B, Reed R C, Nicchitta C V. Virally induced lytic cell death elicits the release of immunogenic grp94/gp96.  J Biol Chem. 2001;  276 21083-21088
• 21 Lorence R M, Rood P A, Kelley K W. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α and augmentation of its cytotoxicity.  J Natl Cancer Institute. 1988;  80 1305-1312
• 22 Stojdl D F, Lichty B, Knowles S. et al . Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.  Nature Medicine. 2000;  6 821-825
• 23 Coffey M, Strong J, Forsyth P. et al . Reovirus therapy of tumors with activated ras pathway.  Science. 1998;  282 1332-1334
• 24 Rommelaere J, Cornelis J J. Antineoplastic activity of parvoviruses.  J Virol Methods. 1991;  33 233-251
• 25 Strong J E, Coffey M C, Tang D. et al . The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.  EMBO J. 1998;  12 3351-3362
• 26 Pecora A L, Rizvi N R, Cohen G I. et al . Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.  J Clin Oncology. 2002;  20 2251-2266
• 27 Hallenbeck P L, Chang Y N, Hay C. et al . A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma.  Human Gene Ther. 1999;  10 1721-1733
• 28 Yamada Y, Takahashi M, Sato Y. et al . Augmented apoptosis-inducing gene therapy for HCC by p53 under control of AFP promoter in combination with a selectively replication-competent oncolytic adenovirus and chemotherapeutic agent.  Mol Ther. 2002;  5 S268
• 29 Ohguchi S, Nakatsukasa H, Higashi T. et al . Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy.  Hepatology. 1998;  27 599-607
• 30 Brunori M, Malerba M, Kashiwazaki H. et al . Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway.  J Virology. 2001;  75 2857-2865
• 31 Powell S, Wang Z, Lemos B. et al . A conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum anti-tumor activity.  Mol Ther. 2002;  5 S19
• 32 Bischoff J R, Kirn D H, Williams A. et al . An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.  Science. 1996;  274 373-376
• 33 Biederer C, Ries S, Brandts C H. et al . Replication-selective viruses for cancer therapy.  J Mol Med. 2002;  80 163-175
• 34 Ganly I, Kirn D, Eckhardt S. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.  Clin Cancer Res. 2000;  6 798-806
• 35 Vasey P, Shukman L, Gore M. et al . Phase I trial of intraperitoneal ONYX-015 adenovirus in patients with recurrent ovarian carcinoma.  Proceedings American Society of Clinical Oncology. 2000;  19 1512
• 36 Reid T. et al . Hepatric artery infusion of ONYX-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestoinal carcinoma metastatic to the liver: A Phase I/II clinical trial.  Proceedings American Society of Clinical Oncology. 2000;  19 953
• 37 Nemunaitis J, Ganly I, Khuri F. et al . Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.  Cancer Res. 2000;  60 6359-6366
• 38 Khuri F, Nemunaitis J, Ganly I. et al . A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.  Nature Medicine. 2000;  6 879-885
• 39 Nemunaitis J, Cunningham C, Buchanan A. et al . Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.  Gene Ther. 2001;  8 746-759
• 40 Hecht R. et al . A phase I/II trial of intratumoral endoscopic injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.  Proceedings American Society of Clinical Oncology. 2000;  19 1039
• 41 Mulvihill S, Warren R, Venook A. et al . Safety and feasibility of injection with an E1B-55 kD gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.  Gene Ther. 2001;  8 308-315
• 42 Yoon S S, Nakamura H, Coroll N M. et al . An oncolytic herpes simplex virus type I selectivley destroys diffuse liver metastases from colon carcinoma.  FASEB J. 2000;  14 301-311
• 43 Pawlik T M, Nakamura H, Yoon S S. et al . Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus.  Cancer Res. 2000;  60 2790-2795
• 44 DeRubertis B G, Stiles B M, Bhargava A. et al . Cytokine secreting oncolytic Herpes Virus effectively treats micrometastatic liver disease in a murine model.  Mol Ther. 2002;  5 S101-S102
• 45 Horsburgh B C, Fong Y, Malhotra S. et al . Multiple administration of NV1020, an oncolytic HSV-1, results in increased anti-tumor efficacy in rodents with colorectal metastases to liver.  Mol Ther. 2002;  5 S148
• 46 Markert J. et al . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malingnant glioma. Results of a phase I trial.  Gene Ther. 2000;  7 867-874
• 47 Mastrangelo M, Eisenlohr L, Gomella L. et al . Poxvirus vevtors: Orphaned and underaprreciated.  J Clin Invest. 2000;  105 1031-1034
• 48 Conry R M. et al . Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic: Comparison of intradermal versus subcutaneous administration.  Clin Cancer Res. 1999;  5 2330-2337
• 49 Hirasawa K, Yoon C, Nishikawa S G. et al . Reovirus therapy of metastatic cancer models in immune-competent mice.  Proc. Am Assoc Cancer Res. 2001;  42 2437a
• 50 Aktelle Informationen des National Cancer Institutes zu dem Klinischen Einsatz von NDV finden sich unter folgender Homepage- Adresse: http://www.cancer.gov/cancer_information/doc.aspx?viewid = 284ad06f-682d-43df-bccf-4943a09c1e98. 
• 51 Roberts M S, Buasen P T, Incao B A. et al . PV 701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts.  Proc Am Assoc Cancer Res. 2001;  42 2441a
• 52 Phuangsab A, Lorence R M, Reichard K W. et al . Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration.  Cancer Letters. 2001;  172 27-36
• 53 Bateman A, Bullough F, Murphy S. et al . Fusogenic membrane glycoproteins as a novel class of genes for local and immune-mediated control of tumor growth.  Cancer Res. 2000;  60 1492-1497
• 54 Enders J, Peebles T. Propagation in tissue culture of cytopathic agents from patients with measles.  Proc Soc Exp Biol Med. 1954;  86 277-286
• 55 Grote D, Russell S J, Corni T I. et al . Live attenuated measle virus induces regression of human lymphoma xenografts in immunodeficient mice.  Blodd. 2001;  97 3746-3754
• 56 Peng K W, Facteau S, Wegman T. et al . Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.  Nature Medicine. 2002;  8 527-531
• 57 Peng K W, TenEyck C T, Galanis E. et al . Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus.  Mol Ther. 2002;  5 S444
• 58 Balachandran S, Porosnicu M, Barber G N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrrant p53, Ras, or Myc function and involves induction of apoptosis.  J Virol. 2001;  75 3474-3479
• 59 Fernandez M, Porosnicu M, Markovic D. et al . Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.  J Virol. 2002;  76 895-904
• 60 Weiss R A. Introducing viruses and cancer. Arrand JR, Harper DR Viruses and Human Cancer Oxford; Bios Scientific Publishers 1-15
• 61 Heise C, Williams A, Olesch J. et al . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects.  Cancer Gene Ther. 1999;  6 499-504
• 62 Douglas J, Kim M, Sumerel L. et al . Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors.  Cancer Res. 2001;  61 499-504
• 63 Yu D. et al . Antitumor synergy of CN787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.  Cancer Res. 2001;  61 517-525
• 64 Heise C, Lemmon M, Kirn D. Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent on sequencing but independent of p53 status.  Clin Cancer Res. 2000;  6 4908-4914
• 65 Sugarbaker P H, Schellinx M E, Chang D. et al . Peritonela carcinomatosis from adenocarcinoma of the colon.  World J Surgery. 1996;  20 585-592
• 66 Rogulski K R, Freytag S O, Zhang K. et al . In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.  Cancer Res. 2000;  60 1193-1196
• 67 Barajas M, Mazzolini G, Genove G. et al . Gene therapy of orthotopic hepatocellular carcinomas in rats using adenovirus coding for interleukin 12.  Hepatology. 2001;  33 52-61
• 68 Habib N A, Mitry R R, Sarraf C E. et al . Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus.  Cancer Gene Ther. 2002;  9 414-420
• 69 Habib N A, Sarraf C E, Mitry R R. et al . E1B deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.  Hum Gene Ther. 2001;  12 219-226
• 70 Reid T, Galanis E, Abbruzzese J. et al . Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase 1 trial.  Gene Ther. 2001;  8 (21) 1618-1626